Bioavailability of intranasal promethazine dosage forms in dogs

Pharmacological Research

Volumn 38, Issue 1, 1998, Pages 35-39

  Ramanathan, Raghupathy ^a   Geary, Richard S ^b   Bourne, David W A ^c   Putcha, Lakshmi ^d  

^a KRUG Life Sciences Inc   (United States)

^b SOUTHWEST RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d NASA JOHNSON SPACE CENTER   (United States)

Author keywords

Dogs; Dosage forms; Intramuscular and intranasal; Pharmacokinetics; Promethazine

Indexed keywords

CARBOXYMETHYLCELLULOSE; GLYCEROL OLEATE; HISTAMINE H1 RECEPTOR ANTAGONIST; MICROSPHERE; PROMETHAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MALE; MOTION SICKNESS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SPACE FLIGHT; WEIGHTLESSNESS;

EID: 0032125546     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1998.0328     Document Type: Article

References (23)

1. 1. Davis JR, Vanderploeg JM, Santy PA, Jennings RT, Stewart DF. Space motion sickness during 24 flights of the space shuttle. Aviat Space Environ Med 1988; 59: 1185-9.
2. 2. Reschke MF, Harm DL, Parker DE, Sandoz GR, Homick JL, Vanderploeg JM. Neurophysiological aspects: space motion sickness. In: Nicogossian AE, Huntoon CL, Pool SL, eds. Space Physiology and Medicine. 3rd ed. Philadelphia: Lea and Febiger, 1994: pp. 228-60.
3. 3. Wood MJ, Wood CD, Manno JE, Manno BR, Redetzki HM. Nuclear medicine evaluation of motion sickness and medications on gastric emptying time. Aviat Space Environ Med 1987; 58: 1112-14.
4. 4. Stewart JJ, Wood MJ, Wood CD, Mims ME. Effects of motion sickness and antimotion sickness drugs on gastric emptying. J Clin Pharmacol 1994; 34: 635-43.
5. 5. Thornton WE, Linder BJ, Moore TP, Pool SL. Gastrointestinal motility in space motion sickness. Aviat Space Environ Med 1987; 58 (suppl): A16-21.
6. 6. Bagian JP. First intramuscular administration in the U.S. space program. J Clin Pharmacol 1991; 31: 920.
7. 7. Davis JR, Jennings RT, Beck BG, Bagian JP. Treatment efficacy of intramuscular promethazine for space motion sickness. Aviat Space Environ Med 1993; 64: 230-3.
8. 8. Wood CD, Graybiel A. Theory of antimotion sickness drug mechanisms. Aerosp Med 1972; 43: 249-52.
9. 9. Physician's Desk Reference. 49th ed. NJ: Medical Economics Data Production Company, 1995: pp. 2711-18.
10. 10. Taylor G, Houston JB, Shaffer J, Mawer G. Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man. Br J Clin Pharmacol 1983; 15: 287-93.
11. 11. Quinn J, Calvert R. The disposition of promethazine in man [proceedings]. J Pharm Pharmacol 1976; 28 (suppl): 59.
12. 12. DiGregorio GJ, Ruch E. Human whole blood and parotid saliva concentrations of oral and intramuscular promethazine. J Pharm Sci 1980; 69: 1457-9.
13. 13. Putcha L, Tietze KJ, Bourne DWA, Parise CM, Hunter RP, Cintrón NM. Bioavailability of intranasal scopolamine in normal subjects. J Pharm Sci 1996; 85: 899-902.
14. 14. Fox AR, McLoughlin DA. Rapid, sensitive high performance liquid chromatographic method for the quantification of promethazine in human serum with electrochemical detection. J Chromatogr 1993; 631: 255-9.
15. 15. Melethil S, Dutta A, Chungi V, Dittert L. Liquid chromatographic assay for promethazine in plasma using electrochemical detection. Anal Lett 1983; 16(B9): 701-09.
16. 16. Zaman R, Honigberg IL, Francisco GE, Kotzan JA, Stewart JT, Brown WJ, Shah VP, Pelsor FR. Bioequivalency and dose proportionality of three tableted promethazine products. Biopharm Drug Dispos 1986; 7: 281-91.
17. 17. Bourne DWA. BOOMER, a simulation and modeling program for pharma-cokinetic and pharmacodynamic data analysis. Comput Methods Programs Biomed 1989; 29: 191-5.
18. 18. Chien YW, Chang SF. Intranasal drug delivery for systematic medications. Crit Rev Ther Drug Carrier Syst 1987; 4(2): 67-194.
19. 19. Cintrón NM, Putcha L, Vanderploeg JM. Inflight salivary pharmacokinetics of scopolamine and dextroamphetamine. In: Results of the Life Sciences DSOs Conducted Aboard the Space Shuttle 1981-1986. Houston, TX: NASA Johnson Space Center, 1987: pp. 25-6.
20. 20. Putcha L, Pool SL, Cintrón, NM. Pharmacology. In: Nicogossian AE, Huntoon CL, Pool SL, eds. Space Physiology and Medicine. 3rd ed. Philadelphia: Lea and Febiger, 1994: pp. 435-46.
21. 21. Schwinghammer TL, Juhl RP, Dittert LW, Melethil SK, Kroboth FJ, Chungi VS. Comparison of the bioavailability of oral, rectal and intramuscular promethazine. Biopharm Drug Dispos 1984; 5:185-94.
22. 22. Drettner B, Aust R, Backlund L, Falk B, Jung B. Comparative measurements of the mucosal blood flow in the human maxillary sinus by plethysmography and by xenon. Acta Otolaryngol (Stockh) 1978; 85: 111.
23. 23. Guyton AC. Muscle blood flow and cardiac output during exercise; the coronary circulation; and ischemic heart disease. Chap 21. In: Text Book of Medical Physiology, 8th ed. WB. Saunders Company, 1991: p. 234.